Voting Rights and Shares Capital of the Company
Nanobiotix has released its monthly report on voting rights and share capital as of October 31, 2024. The company reported 47,426,851 shares outstanding, with 49,201,086 theoretical voting rights and 49,178,968 exercisable voting rights. The company's shares are listed on both Euronext Paris and Nasdaq under the ticker symbol NBTX.
Nanobiotix ha pubblicato il suo rapporto mensile sui diritti di voto e sul capitale sociale al 31 ottobre 2024. L'azienda ha riportato 47.426.851 azioni in circolazione, con 49.201.086 diritti di voto teorici e 49.178.968 diritti di voto esercitabili. Le azioni dell'azienda sono quotate sia su Euronext Paris che su Nasdaq con il simbolo di ticker NBTX.
Nanobiotix ha publicado su informe mensual sobre los derechos de voto y el capital social al 31 de octubre de 2024. La empresa informó de 47.426.851 acciones en circulación, con 49.201.086 derechos de voto teóricos y 49.178.968 derechos de voto ejercitables. Las acciones de la empresa están cotizadas tanto en Euronext París como en Nasdaq bajo el símbolo de ticker NBTX.
Nanobiotix는 2024년 10월 31일 기준으로 투표권 및 자본금에 대한 월간 보고서를 발표했습니다. 회사는 47,426,851주의 유통 주식과 49,201,086개의 이론적 투표권, 49,178,968개의 행사 가능한 투표권을 보고했습니다. 회사의 주식은 Euronext Paris와 Nasdaq에 NBTX라는 티커 기호로 상장되어 있습니다.
Nanobiotix a publié son rapport mensuel sur les droits de vote et le capital social au 31 octobre 2024. La société a annoncé avoir 47.426.851 actions en circulation, avec 49.201.086 droits de vote théoriques et 49.178.968 droits de vote exerçables. Les actions de l'entreprise sont cotées sur Euronext Paris et Nasdaq sous le symbole NBTX.
Nanobiotix hat seinen monatlichen Bericht über Stimmrechte und das Grundkapital zum 31. Oktober 2024 veröffentlicht. Das Unternehmen berichtete von 47.426.851 ausgegebenen Aktien, mit 49.201.086 theoretischen Stimmrechten und 49.178.968 ausübbaren Stimmrechten. Die Aktien des Unternehmens sind sowohl an der Euronext Paris als auch an der Nasdaq unter dem Tickersymbol NBTX gelistet.
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE) --
Paris, France, November 13, 2024
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| October 31, 2024 | 47,426,851 | 49,201,086 | 49,178,968 |
***
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
Attachments
FAQ
How many shares does Nanobiotix (NBTX) have outstanding as of October 31, 2024?
What is the total number of theoretical voting rights for Nanobiotix (NBTX) as of October 2024?
What is the difference between theoretical and exercisable voting rights for NBTX as of October 2024?
